InvestSMART

AnteoTech Limited (ASX:ADO)

ALERT: Price-sensitive ASX Announcement for ADO
Current share price for ADO : $0.028 0.011 (64.71%)+
Announcement
Release
29 Dec 2025 8:48AM
Price at Release
$0.017
Full Release
download
Summary
AnteoTech Limited, an advanced materials supplier, has received a significant order from the Serum Institute of India for its AnteoBind™ product, valued at approximately AU$275,750. This order is part of a five-year supply agreement and is scheduled for dispatch in early January 2026. AnteoTech is also advancing its Life Sciences division by evaluating a new prototype product with the Serum Institute and other global entities. The company has seen successful sales growth, particularly in Japan, and is focusing on expanding its presence in the global immunoassay market, specifically in the ELISA and CLIA segments. AnteoBind™ is noted for its performance and cost benefits, which have been validated through comparative studies and peer-reviewed publications. The company anticipates further growth in 2026, driven by strategic partnerships and targeted marketing efforts.
Key Points
  • Received a US$185,000 order for AnteoBind from the Serum Institute of India.
  • New AnteoBind sales secured with Japanese customers for approximately AU$70,000.
  • Initiated 10 new AnteoBind NXT evaluations globally since September 2025.
  • Prototype product developments with large global life sciences companies are underway.
  • AnteoBind NXT offers significant performance and cost benefits over traditional Tosyl chemistry.
  • Company plans to move AnteoBind from an additive to a core ingredient for major market segments.
  • Several peer-reviewed publications highlight AnteoBind's advantages.
  • Continued engagement with Vidcare strengthens presence in the Indian market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.